GSK Stock Analysis: GlaxoSmithKline | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 101.042m USD | 12M Return: 34.3% | US37733W2044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 198M
EPS Trend: 96.8%
Qual. Beats: 10
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GSK plc is a UK-headquartered global pharmaceutical company that discovers, develops, manufactures, and commercializes vaccines, specialty medicines, and general medicines across the UK, the US, and international markets. The company operates through two segments: Commercial Operations and Total R&D, a structure that separates its sales and distribution activities from its drug discovery and development pipeline. Founded in 1715 and originally known as GlaxoSmithKline before rebranding to GSK in May 2022, it is among the longest-established players in the global pharmaceuticals industry.
Its portfolio spans specialty medicines in oncology, respiratory/immunology, and inflammation (including treatments for HIV, lupus, ovarian, and endometrial cancer); a broad vaccines franchise covering shingles, meningitis, RSV, influenza, hepatitis, HPV, and others; and general medicines addressing asthma, COPD, allergic rhinitis, and inflammatory skin conditions. As a large-cap health care company in the GICS Pharmaceuticals sub-industry, GSK competes in a sector characterized by long product development cycles, heavy R&D expenditure, and revenue dependence on patent-protected molecules and vaccine contracts. The company also pursues external innovation through partnerships, including an mRNA vaccine collaboration with CureVac and a TB therapy alliance with AN2 Therapeutics.
- Shingrix vaccine demand recovery lifts vaccine segment revenue
- ViiV HIV franchise margins expand as dolutegravir exclusivity holds
- Arexvy RSV vaccine faces Pfizer and Moderna competition in US market
| Net Income: 4.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.63 > 1.0 |
| NWC/Revenue: -11.90% < 20% (prev -11.72%; Δ -0.18% < -1%) |
| CFO/TA 0.14 > 3% & CFO 8.74b > Net Income 4.82b |
| Net Debt (15.9b) to EBITDA (10.9b): 1.46 < 3 |
| Current Ratio: 0.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.03b) vs 12m ago -1.17% < -2% |
| Gross Margin: 72.73% > 18% (prev 71.36%; Δ 1.36% > 0.5%) |
| Asset Turnover: 46.58% > 50% (prev 38.95%; Δ 7.63% > 0%) |
| Interest Coverage Ratio: 9.56 > 6 (EBIT TTM 6.59b / Interest Expense TTM 690.0m) |
| A: -0.06 (Total Current Assets 17.5b - Total Current Liabilities 21.4b) / Total Assets 61.4b |
| B: 0.19 (Retained Earnings 11.4b / Total Assets 61.4b) |
| C: 0.09 (EBIT TTM 6.59b / Avg Total Assets 71.3b) |
| D: 0.40 (Book Value of Equity 17.5b / Total Liabilities 44.3b) |
| Altman-Z'' = 1.22 = BB |
| DSRI: 0.72 (Receivables 8.03b/10.5b, Revenue 33.2b/31.6b) |
| GMI: 0.98 (GM 71.36% / 72.73%) |
| AQI: 1.03 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.05 (Revenue 33.2b / 31.6b) |
| TATA: -0.06 (NI 4.82b - CFO 8.74b) / TA 61.4b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of August 22, 2026, the stock is trading at USD 52.41 with a total of 2,404,628 shares traded. Over the past week, the price has changed by +3.92%, over one month by +4.78%, over three months by +3.25% and over the past year by +34.27%.
Current recommended Stop Loss: 50.10 (which is 4.4% or 1.9 ATR below the current price).
GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold GSK.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 58.1 | 10.8% |
Market Cap GBP = 74.1b (101b USD * 0.733 USD.GBP)
P/E Trailing = 15.815
P/E Forward = 21.0526
P/S = 3.0431
P/B = 4.3888
P/EG = 105.1841
Revenue TTM = 33.2b GBP
EBIT TTM = 6.59b GBP
EBITDA TTM = 10.9b GBP
Long Term Debt = 14.0b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 4.27b GBP (from shortTermDebt, last quarter)
Debt = 19.0b GBP (from shortLongTermDebtTotal, last quarter) + Leases 830.0m
Net Debt = 15.9b GBP (calculated: Debt 19.0b - CCE 3.09b)
Enterprise Value = 89.9b GBP (74.1b + Debt 19.0b - CCE 3.09b)
Interest Coverage Ratio = 9.56 (Ebit TTM 6.59b / Interest Expense TTM 690.0m)
EV/FCF = 12.88x (Enterprise Value 89.9b / FCF TTM 6.98b)
FCF Yield = 7.76% (FCF TTM 6.98b / Enterprise Value 89.9b)
FCF Margin = 21.02% (FCF TTM 6.98b / Revenue TTM 33.2b)
Net Margin = 14.52% (Net Income TTM 4.82b / Revenue TTM 33.2b)
Gross Margin = 72.73% ((Revenue TTM 33.2b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Gross Margin QoQ = 73.05% (prev 75.42%)
Tobins Q-Ratio = 1.47 (Enterprise Value 89.9b / Total Assets 61.4b)
Interest Expense / Debt = 3.64% (Interest Expense 690.0m / Debt 19.0b)
Taxrate = 10.86% (641.0m / 5.90b)
NOPAT = 5.88b (EBIT 6.59b * (1 - 10.86%))
Current Ratio = 0.82 (Total Current Assets 17.5b / Total Current Liabilities 21.4b)
Debt / Equity = 1.08 (Debt 19.0b / totalStockholderEquity, last quarter 17.5b)
Debt / EBITDA = 1.46 (Net Debt 15.9b / EBITDA 10.9b)
Debt / FCF = 2.27 (Net Debt 15.9b / FCF TTM 6.98b)
Total Stockholder Equity = 19.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.76% (Net Income 4.82b / Total Assets 61.4b)
RoE = 24.36% (Net Income TTM 4.82b / Total Stockholder Equity 19.8b)
RoCE = 19.50% (EBIT 6.59b / Capital Employed (Equity 19.8b + L.T.Debt 14.0b))
RoIC = 13.81% (NOPAT 5.88b / Invested Capital 42.6b)
WACC = 5.74% (E(74.1b)/V(93.0b) * Re(6.38%) + D(19.0b)/V(93.0b) * Rd(3.64%) * (1-Tc(0.11)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -61.61 | Cagr: -0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈6.05b ; Y1≈6.94b ; Y5≈10.2b
[DCF] Fair Price = 68.82 (EV 154b - Net Debt 15.9b = Equity 138b / Shares 2.00b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.85 | EPS CAGR: 8.26% | SUE: 2.30 | # QB: 10
Revenue Correlation: 96.73 | Revenue CAGR: 3.58% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.34 | Chg30d=-4.95% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=4.75 | Chg30d=-0.78% | Revisions=+0% | GrowthEPS=+0.8% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=5.14 | Chg30d=+0.17% | Revisions=+0% | GrowthEPS=+8.2% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +0% (up=3, down=3)